The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
WHO Executive Board, 144th Session, January 2019 MSF Statement: Agenda item 5.8.3 (EB144/21) – Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Ending tuberculosis
WHO Executive Board, 144th Session, January 2019 MSF Statement: Agenda item 5.7.1 (EB144/17) – Medicines, vaccines and health products: Access to medicines and vaccines